BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Perflutren Microsphere

Serious Cardiopulmonary Reactions

Perflutren Lipid Microsphere (Definity)

  • Serious cardioplumonary reactions, including fatalities have occurred uncommonly during or following perflutren containing microsphere administration. Most serious reactions occur within 30 minutes of administration.
  • Assess all patients for the presence of any condition that precludes administration of Perflutren Lipid Microsphere (Definity)  (See CONTRAINDICATIONS)
  • Always have resuscitation equipment and trained personnel readily available (See WARNINGS) .

 

Perflutren Protein-Type A Microspheres (Optison)

  • Serious cardioplumonary reactions, including fatalities have occurred during or following perflutren containing microsphere administration.
  • Assess all patients for the presence of any condition that precludes administration of Perflutren Protein-Type A Microspheres (Optison). 
  • In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor patients during and for at least 30 minutes following administration, including vital signs, electrocardiography and cutaneous oxygen saturation. 
  • Always have resuscitation equipment and trained personnel readily available .

 


FDA and Industry Communications

Index to FDA Drug Safety Information

Patient Counseling Information

Package Inserts

Perflutren

Additional Information

Updated January 2018